Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Cancers|September 28, 2023
Current Status of Angiogenesis Inhibitors as Second-Line Treatment for Unresectable Colorectal CancerSatoshi Otsu, Shuichi Hironaka
BMJ Case Reports|July 9, 2013
CD34-negative solitary fibrous tumour resistant to imatinibKoichiro Watanabe, Satoshi Otsu, Ryotaro Morinaga, et al.
Japanese Clinical Medicine|September 12, 2014
Neurological Toxicity in Metastatic Colorectal Cancer Patients Treated with Modified FOLFOX6 Plus BevacizumabSatoshi Otsu, Yoshinori Hirashima, Kazuo Nishikawa, et al.
Infection and Immunity|January 24, 2006
Transfer of antigen-pulsed dendritic cells induces specific T-Cell proliferation and a therapeutic effect against long-term Helicobacter pylori infection in miceSatoshi Otsu, Kazuyo Gotoh, Tetsu Yamashiro, et al.
BMC Gastroenterology|November 3, 2010
Vesicocutaneous fistula formation during treatment with sunitinib malate: Case reportKoichiro Watanabe, Satoshi Otsu, Ryotaro Morinaga, et al.
Helicobacter|September 12, 2006
Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infectionKazunari Murakami, Tadayoshi Okimoto, Masaaki Kodama, et al.
Future Oncology (London, England)|August 16, 2023
Phase II biomarker identification study of anti-VEGF agents with FOLFIRI for pretreated metastatic colorectal cancerTadayoshi Hashimoto, Satoshi Otsu, Shuichi Hironaka, et al.
Clinical Pharmacology and Therapeutics|March 17, 2025
Impact of Cancer Cachexia Progression on OATP1B1 Transport Activity: Quantitative Analysis Using Coproporphyrin-I as an Endogenous BiomarkerTakahiro Sumimoto, Ryota Tanaka, Yosuke Suzuki, et al.
Japanese Journal of Clinical Oncology|September 1, 2022
A multicentre retrospective study comparing site-specific treatment with empiric treatment for unfavourable subset of cancer of unknown primary siteKazuo Nishikawa, Shuichi Hironaka, Takashi Inagaki, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|December 6, 2018
Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trialToshihiko Doi, Satoru Iwasa, Kei Muro, et al.
Pageof 5